FIELD: medicine.
SUBSTANCE: invention refers namely to pharmaceutical industry, and concerns tablets with the slowed down liberation, containing alfuzosin hydrochloride. The tablet includes: the top layer including 0,2 weight parts of alfuzosin HC1, 90 weight. parts of hypromellose, 29. 6 weight parts of polyethylene oxide, 1 weight part of stearyl alcohol, 0.4 weight parts of easy waterless silicon acid and 1 weight part of ethyl cellulose; and the bottom layer including 9.8 weight parts alfuzosin HC1, 36-62 weight parts of microcrystalline cellulose, 24-60 weight parts of polyethylene oxide, 20 weight parts low substituted hydroxypropyl cellulose, 1-6 weight parts of stearyl alcohol and 99 weights parts of hydroxypropyl cellulose.
EFFECT: received tablet is characterized by the liberation of the medicine with the curve of the zero order.
3 cl, 2 tbl, 10 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PROLONGED RELEASE TABLET CONTAINING THEOBROMIN | 2010 |
|
RU2506947C2 |
| STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2013 |
|
RU2614382C2 |
| PHARMACEUTICAL COMPOSITIONS, CONTAINING IMATINIB AND RELEASE MODERATOR | 2006 |
|
RU2404775C2 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
| ORAL DOSAGE FORMS OF TOFACITINIB WITH CONTINUOUS RELEASE | 2014 |
|
RU2790166C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| HARD, SUITABLE FOR ORAL INTAKE PHARMACEUTICAL FORMS OF APPLICATION, CONTAINING RIVAROXABAN WITH MODIFIED RELEASE | 2005 |
|
RU2420290C2 |
| COMPOSITION WITH RAPID ONSET EFFECT | 2001 |
|
RU2266744C2 |
| GASTRAL RETENTIVE COMPOSITIONS AND ITS PRODUCTION METHODS | 2006 |
|
RU2376983C2 |
| PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2470637C2 |
